About GLP-1 Guide

GLP-1 Guide is an independent resource focused on GLP-1 medications, telehealth providers, dosing protocols, side-effect management, and the broader weight-management landscape. We cover the entire GLP-1 category — from FDA-approved drugs (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Rybelsus, Trulicity, Victoza) to pipeline candidates (retatrutide, orforglipron, CagriSema) to non-GLP-1 alternatives.

Our Editorial Approach

We base content on FDA labeling, peer-reviewed clinical trials (STEP, SURMOUNT, SELECT, SURPASS, etc.), manufacturer disclosures, and real-world telehealth provider data. We update content regularly to reflect new approvals, indication expansions, pricing changes, and trial results.

How We Make Money

GLP-1 Guide receives compensation when readers click through to telehealth providers from our site and complete a sign-up. This affiliate relationship does not influence editorial assessments. We rate every provider on price, drug menu, transparency, and user experience independent of compensation. We disclose this relationship on every page.

What We Are Not

• We are not a medical practice. We do not provide medical advice.
• We are not affiliated with any pharmaceutical manufacturer.
• We are not a telehealth provider. We compare them.
• We do not sell products directly.

Contact

Editorial inquiries: editorial at glp-1.eu.com